vs
STANDARD BIOTOOLS INC.（LAB）与MVB FINANCIAL CORP（MVBF）财务数据对比。点击上方公司名可切换其他公司
MVB FINANCIAL CORP的季度营收约是STANDARD BIOTOOLS INC.的1.9倍（$36.7M vs $19.6M），MVB FINANCIAL CORP净利率更高（0.0% vs -177.4%，领先177.4%），过去两年MVB FINANCIAL CORP的营收复合增速更高（2.8% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
MVB金融公司是总部位于美国西弗吉尼亚州的金融控股企业，主要提供商业与零售银行服务、财富管理、抵押贷款及存款产品，同时面向金融科技、游戏领域企业提供专项数字银行解决方案，服务覆盖美国中大西洋地区。
LAB vs MVBF — 直观对比
营收规模更大
MVBF
是对方的1.9倍
$19.6M
净利率更高
MVBF
高出177.4%
-177.4%
两年增速更快
MVBF
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $36.7M |
| 净利润 | $-34.7M | $0 |
| 毛利率 | 48.5% | — |
| 营业利润率 | -168.5% | — |
| 净利率 | -177.4% | 0.0% |
| 营收同比 | -11.5% | — |
| 净利润同比 | -28.8% | — |
| 每股收益（稀释后） | $-0.09 | $0.39 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABMVBF
| Q1 26 | — | $36.7M | ||
| Q4 25 | — | $39.1M | ||
| Q3 25 | $19.6M | $61.2M | ||
| Q2 25 | $21.8M | $33.7M | ||
| Q1 25 | $40.8M | $33.7M | ||
| Q4 24 | — | $46.2M | ||
| Q3 24 | $22.1M | $33.2M | ||
| Q2 24 | $22.5M | $34.7M |
净利润LABMVBF
| Q1 26 | — | $0 | ||
| Q4 25 | — | $4.2M | ||
| Q3 25 | $-34.7M | $17.1M | ||
| Q2 25 | $-33.5M | $2.0M | ||
| Q1 25 | $-26.0M | $3.6M | ||
| Q4 24 | — | $9.4M | ||
| Q3 24 | $-26.9M | $2.1M | ||
| Q2 24 | $-45.7M | $4.1M |
毛利率LABMVBF
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 48.5% | — | ||
| Q2 25 | 48.8% | — | ||
| Q1 25 | 48.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 54.9% | — | ||
| Q2 24 | 46.1% | — |
营业利润率LABMVBF
| Q1 26 | — | — | ||
| Q4 25 | — | 13.9% | ||
| Q3 25 | -168.5% | 38.3% | ||
| Q2 25 | -118.1% | 9.4% | ||
| Q1 25 | -80.8% | 14.3% | ||
| Q4 24 | — | 26.5% | ||
| Q3 24 | -120.9% | 8.4% | ||
| Q2 24 | -134.5% | 15.9% |
净利率LABMVBF
| Q1 26 | — | 0.0% | ||
| Q4 25 | — | 10.8% | ||
| Q3 25 | -177.4% | 28.0% | ||
| Q2 25 | -153.7% | 5.9% | ||
| Q1 25 | -63.8% | 10.6% | ||
| Q4 24 | — | 20.4% | ||
| Q3 24 | -122.0% | 6.3% | ||
| Q2 24 | -203.3% | 11.8% |
每股收益（稀释后）LABMVBF
| Q1 26 | — | $0.39 | ||
| Q4 25 | — | $0.32 | ||
| Q3 25 | $-0.09 | $1.32 | ||
| Q2 25 | $-0.09 | $0.15 | ||
| Q1 25 | $-0.07 | $0.27 | ||
| Q4 24 | — | $0.72 | ||
| Q3 24 | $-0.07 | $0.16 | ||
| Q2 24 | $-0.12 | $0.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $177.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $334.9M |
| 总资产 | $539.6M | $3.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LABMVBF
| Q1 26 | — | $177.6M | ||
| Q4 25 | — | $244.1M | ||
| Q3 25 | $129.4M | $300.0M | ||
| Q2 25 | $158.6M | $399.4M | ||
| Q1 25 | $150.9M | $251.4M | ||
| Q4 24 | — | $317.9M | ||
| Q3 24 | $210.6M | $610.9M | ||
| Q2 24 | $269.8M | $455.5M |
总债务LABMVBF
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — |
股东权益LABMVBF
| Q1 26 | — | $334.9M | ||
| Q4 25 | — | $334.0M | ||
| Q3 25 | $399.7M | $327.8M | ||
| Q2 25 | $424.5M | $302.3M | ||
| Q1 25 | $454.6M | $310.1M | ||
| Q4 24 | — | $305.7M | ||
| Q3 24 | $489.3M | $303.1M | ||
| Q2 24 | $510.3M | $296.6M |
总资产LABMVBF
| Q1 26 | — | $3.3B | ||
| Q4 25 | — | $3.3B | ||
| Q3 25 | $539.6M | $3.2B | ||
| Q2 25 | $557.0M | $3.2B | ||
| Q1 25 | $579.6M | $3.0B | ||
| Q4 24 | — | $3.1B | ||
| Q3 24 | $681.5M | $3.4B | ||
| Q2 24 | $708.7M | $3.3B |
负债/权益比LABMVBF
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | — |
| 自由现金流率自由现金流/营收 | -118.1% | — |
| 资本支出强度资本支出/营收 | 4.5% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-111.1M | — |
8季度趋势，按日历期对齐
经营现金流LABMVBF
| Q1 26 | — | — | ||
| Q4 25 | — | $4.0M | ||
| Q3 25 | $-22.2M | $-2.6M | ||
| Q2 25 | $-20.7M | $7.4M | ||
| Q1 25 | $-30.3M | $14.1M | ||
| Q4 24 | — | $-285.0K | ||
| Q3 24 | $-27.9M | $8.6M | ||
| Q2 24 | $-39.0M | $26.9M |
自由现金流LABMVBF
| Q1 26 | — | — | ||
| Q4 25 | — | $2.1M | ||
| Q3 25 | $-23.1M | $-3.5M | ||
| Q2 25 | $-22.6M | $7.2M | ||
| Q1 25 | $-35.3M | $13.9M | ||
| Q4 24 | — | $-1.9M | ||
| Q3 24 | $-30.1M | $8.3M | ||
| Q2 24 | $-41.0M | $26.6M |
自由现金流率LABMVBF
| Q1 26 | — | — | ||
| Q4 25 | — | 5.4% | ||
| Q3 25 | -118.1% | -5.8% | ||
| Q2 25 | -103.6% | 21.5% | ||
| Q1 25 | -86.6% | 41.2% | ||
| Q4 24 | — | -4.1% | ||
| Q3 24 | -136.4% | 25.1% | ||
| Q2 24 | -182.2% | 76.7% |
资本支出强度LABMVBF
| Q1 26 | — | — | ||
| Q4 25 | — | 4.9% | ||
| Q3 25 | 4.5% | 1.6% | ||
| Q2 25 | 8.7% | 0.6% | ||
| Q1 25 | 12.4% | 0.8% | ||
| Q4 24 | — | 3.5% | ||
| Q3 24 | 10.2% | 0.9% | ||
| Q2 24 | 8.6% | 0.7% |
现金转化率LABMVBF
| Q1 26 | — | — | ||
| Q4 25 | — | 0.95× | ||
| Q3 25 | — | -0.15× | ||
| Q2 25 | — | 3.72× | ||
| Q1 25 | — | 3.95× | ||
| Q4 24 | — | -0.03× | ||
| Q3 24 | — | 4.15× | ||
| Q2 24 | — | 6.57× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
MVBF
| Net Interest Income | $28.5M | 78% |
| Noninterest Income | $8.2M | 22% |
